The Power of Your Immune System: PersonaVaxTM
The Problem: Metastatic Cancer
No therapy can extend median survival more than a few months in those with metastatic prostate cancer Unfortunately, the same situation also applies for most other cancers.
The Solution: Multiplex Combination ImmunotherapyTM and PersonaVaxTM
Multiplex is the use of different methods like Ablation Therapy, Immunotherapy Drugs, and Low-Dose Chemotherapy Drug for modulating the immune system at the same time.
PersonaVaxTM is the the combination of drugs we’ve developed for Multiplex Combination ImmunotherapyTM, which uses the patient’s own immune system to destroy cancer and Ablation to directly kill cancer cells and release all cancer-associated proteins.
Ablation kills cancer cells, releasing cancer-specific proteins
Immunotherapy unmasks (de-cloaks) individual cancer cells
Immunotherapy and low-dose chemotherapy block the “off”
Immunotherapy stimulates the immune system to kill cancer cells
|# Immune System Targets||3||1 or 2|
|# Cancer-Associated Antigens||Innumerable, personalized||1 – 5, often pre-selected|
|Drug Dosing||Low-dose for all drugs||Maximum tolerated dose|
|Drug Injections||Intratumoral or Intradermal depot||Systemic (intravenous)|
|Serious Adverse Event Rate||18%1||24%2 (Provenge)|
|Abscopal Event Rate||75%1||< 1%2 (Provenge)|
|Radiographic Response Rate||75%1||0%2 (Provenge)|
Successfully bringing combination immunotherapy to market presents a unique set of challenges that requires both legal and scientific expertise to manage.
Rampart Health pursues IP strategies that build on its combined scientific and legal expertise to develop and expand proprietary technologies designed to mitigate risk and enable treatment innovation.
We invest in discovering and advancing technologies to speed development of combination immunotherapy to all cancer patients in need.